NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory MM
- Active, not recruiting
- Jun 9, 2021
- 1 min read
Updated: Jul 18, 2022
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
NCT04892446: Phase 2: Study of Magrolimab Combinations in Participants With Relapsed/Refractory Multiple Myeloma
The primary objective of this study for the Safety Run-in Cohorts is to evaluate the safety and tolerability of magrolimab in combination with other anticancer therapies and to determine the recommended Phase 2 dose (RP2D) of magrolimab in participants with relapsed/refractory multiple myeloma (MM) for the following combinations: magrolimab + daratumumab, magrolimab + pomalidomide + dexamethasone, and magrolimab + bortezomib + dexamethasone.
The primary objective of this study for the Dose Expansion Cohorts is to evaluate the efficacy of magrolimab in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma as determined by objective response rate (ORR).
Sponsor
ClinicalTrials.gov Identifier: NCT04892446
Official Title: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
First Posted : May 19, 2021
Click here for details on ClinicalTrials.gov
Magrolimab (Code C117730)
Hu5F9-G4
Magrolimab
MAGROLIMAB
anti-CD47 monoclonal antibody Hu5F9-G4
Hu5F9-G4
ONO-7913
Biological: Magrolimab
Drug: Daratumumab
Drug: Pomalidomide
Drug: Dexamethasone
Drug: Bortezomib
Drug: Carfilzomib
Location
United States, Arizona
United States, California
United States, Michigan
United States, North Carolina
United States, Oregon
United States, Texas
United States, Virginia